▲ +338.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for GlycoMimetics in the last 3 months. The average price target is $15.00, with a high forecast of $15.00 and a low forecast of $15.00. The average price target represents a 338.60% upside from the last price of $3.42.
The current consensus among 3 contributing investment analysts is to buy stock in GlycoMimetics. This Buy consensus rating has held steady for over two years.
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's drug candidate include rivipansel, a pan-selectin antagonist, which has completed Phase III clinical trial for the treatment of vaso-occlusive crisis in sickle cell disease. It is also developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML. In addition, the company offers GMI-1359 that has completed Phase I clinical trial to target E-selectin and a chemokine receptor for various tumor types. It also develops various other programs, including GMI-1687, an antagonist of E-selectin; and Galectin-3, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and collaboration and license agreement with Apollomics for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.